STOP-HER2: Stopping Trastuzumab in HER2+ MBC | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
STOP-HER2: Stopping Trastuzumab in HER2+ MBC	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 2	2026-08-06		NCT05721248

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Dana-Farber Cancer Institute	324
Gateway for Cancer Research	32
Johns Hopkins University	579
National Cancer Institute (NCI)	3015
Susan G. Komen Breast Cancer Foundation	16
Translational Breast Cancer Research Consortium	19

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Baylor College of Medicine	Houston	United States	306
Dana-Farber Cancer Insitute	Boston	United States	3
DFCI @ Foxborough	Foxborough	United States	3
DFCI @ Merrimack Valley	Methuen	United States	1
DFCI @ Milford Regional Hospital	Milford	United States	3
DFCI @ South Shore Hospital	South Weymouth	United States	2
Duke University	Durham	United States	160
Fred Hutchinson Cancer Center	Seattle	United States	250
Georgetown University Medical Center	Washington D.C.	United States	1
Mayo Clinic Hospital Arizona	Phoenix	United States	2
Mayo Clinic Rochester	Rochester	United States	133
Mayo Clinical Hospital Florida	Jacksonville	United States	2
University of Pittsburgh Medical Center	Pittsburgh	United States	127